SCHEMBL144202

SCHEMBL144202

NC(=S)Nc1c(F)cc(F)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
MAPT P10636 2/20 0.50
GAA P10253 1/20 0.41
ALDH1A1 P00352 4/20 0.37
TP53 P04637 1/20 0.37
TYR P14679 1/20 0.37
TSHR P16473 1/20 0.37
TAS2R38 P59533 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CTSL P07711 2/20 0.36
RAPGEF4 Q8WZA2 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
PPP5C P53041 1/20 0.35
CYP1A2 P05177 1/20 0.34
FUCA1 P04066 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6832781 0.86 MAPT (0.44) KMT2AMAPTGAAALDH1A1TP53
SCHEMBL28340396 0.83 KMT2A (0.37) KMT2AMAPTGAAALDH1A1TP53
SCHEMBL15484309 0.81 MAPT (0.58) KMT2AMAPTGAAALDH1A1RAPGEF4
SCHEMBL18550697 0.78 L3MBTL1 (0.40) KMT2AMAPTGAAALDH1A1RAPGEF4
SCHEMBL1192648 0.78 GAA (0.67) KMT2AMAPTGAAALDH1A1TP53
SCHEMBL457132 0.78 MAPT (0.77) KMT2AMAPTGAAALDH1A1
SCHEMBL20560235 0.77 MAPT (0.46) KMT2AMAPTGAAALDH1A1RAPGEF4
SCHEMBL1885075 0.77 KMT2A (0.48) KMT2AMAPTGAAALDH1A1TP53
SCHEMBL11883304 0.77 KMT2A (0.42) KMT2AMAPTGAAALDH1A1RAPGEF4
SCHEMBL5154372 0.77 ALDH1A1 (0.48) KMT2AMAPTALDH1A1RAPGEF4FUCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230129765-A1 METHOD FOR PRODUCING POLYTHIOETHER COMPOUND DAICEL CORPORATION (JP) 2023-04-27 US disclosed
EP-4108705-A1 METHOD FOR PRODUCING POLYTHIOETHER COMPOUND Daicel Corporation (JP) 2022-12-28 EP disclosed
CN-115135697-A Process for producing polythioether compound 株式会社大赛璐 2022-09-30 CN disclosed
CN-113278149-A Process for producing polythioether compound 株式会社大赛璐 2021-08-20 CN disclosed
EP-2700636-B1 PROCESS FOR PREPARING EPISULFIDE COMPOUNDS ASAHI CHEMICAL IND (JP) 2017-08-02 EP disclosed
CN-103717593-B Regulate kinase whose compositions and method 克勒韦谢尔制药公司 2016-07-06 CN disclosed
US-9359324-B2 Process for preparing episulfide compounds ASAHI KASEI CHEMICALS CORPORATION (JP) 2016-06-07 US disclosed
CN-103476764-B Process for producing episulfide compound ASAHI KASEI KABUSHIKI KAISHA (JP) 2016-05-25 CN disclosed
EP-2718290-B1 COMPOSITIONS AND METHODS FOR MODULATING A KINASE CLEVEXEL PHARMA (FR) 2016-05-04 EP disclosed
US-20150197501-A1 Process for Preparing Episulfide Compounds ASAHI KASEI CHEMICALS CORPORATION (JP) 2015-07-16 US disclosed
US-8937065-B2 Compositions and methods for modulating a kinase CLEVEXEL PHARMA (FR) 2015-01-20 US disclosed
US-8937065-B2 Compositions and methods for modulating a kinase CLEVEXEL PHARMA (FR) 2015-01-20 US disclosed
US-20140107350-A1 Process for Preparing Episulfide Compounds ASAHI KASEI CHEMICALS CORPORATION (JP) 2014-04-17 US disclosed
EP-2700636-A1 PROCESS FOR PREPARING EPISULFIDE COMPOUNDS Asahi Kasei Chemicals Corporation (JP) 2014-02-26 EP disclosed
CN-103476764-A Process for producing episulfide compound ASAHI KASEI CHEMICALS CORP (JP) 2013-12-25 CN disclosed
WO-2012172438-A9 COMPOSITIONS AND METHODS FOR MODULATING A KINASE DYNAMIX PHARMACEUTICALS LTD. (IL) 2013-02-07 WO disclosed
WO-2012172438-A2 COMPOSITIONS AND METHODS FOR MODULATING A KINASE DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-12-20 WO disclosed
US-20120059163-A1 Non-linear opticaly active molecules, their synthesis, and use OPTIMER PHOTONICS, INC. (US) 2012-03-08 US disclosed
US-20080004415-A1 Non-linear optically active molecules, their synthesis, and use OPTIMER PHOTONICS, INC. (US) 2008-01-03 US disclosed
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197501-A1 Process for Preparing Episulfide Compounds TST, EPHX2, STS KMT2A 867/4885MAPT 4698/4885GAA 4338/4885
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 KMT2A 792/4885MAPT 680/4885GAA 266/4885
US-20120059163-A1 Non-linear opticaly active molecules, their synthesis, and use INCENP, CYBA, ADCY5 KMT2A 3041/4885MAPT 2242/4885GAA 2311/4885
US-20080004415-A1 Non-linear optically active molecules, their synthesis, and use INCENP, CYBA, PAICS KMT2A 2961/4885MAPT 2173/4885GAA 1748/4885
US-20140107350-A1 Process for Preparing Episulfide Compounds TST, EPHX2, STS KMT2A 867/4885MAPT 4698/4885GAA 4338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.